Marketing Approval Expands Treatment to Include Nearly 11 Million Patients Who Experience Opioid-Induced Constipation While Taking Opioids for Chronic Non-Cancer Pain RALEIGH, N.C. & TARRYTOWN, N.Y.-- ...

Progenics Pharmaceuticals announced that it will hand over commercial duties on Relistor, a subcutaneous injection for opioid-induced constipation (OIC), to Salix, beginning in April. Financial terms ...

TARRYTOWN, N.Y., Oct 14, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it has entered into an agreement with Wyeth Pharmaceuticals, a division of Wyeth ...

RELISTOR(R) (methylnaltrexone bromide) is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic ...

TARRYTOWN, N.Y.--(BUSINESS WIRE)-- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced it has extended its agreement with Wyeth (now a subsidiary of Pfizer Inc.) to continue Wyeth’s ...

TARRYTOWN, N.Y. & RALEIGH, N.C.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) and Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) today announced that they have entered into an exclusive ...

Please provide your email address to receive an email when new articles are posted on . A single dose of Relistor injection produced rescue-free laxation in severely ill patients with opioid-induced ...

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced the Therapeutic Goods Administration (TGA) division of the Australian Government has approved the ...

Data from a Post-Hoc Analysis Supports the Use of Salix's RELISTOR for Patients with Opioid-Induced Constipation and Advanced Illness in the Emergency Department Setting LAVAL, QC, Dec. 22, 2021 ...

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it has entered into an agreement with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) under ...